C-ARYL GLUCOSIDE SGLT2 INHIBITORS
Brazil
Stats

Importance

BR Family Size
|
Non-US Coverage
|
Abstract
inibidores sglt2 de glicosídeo c-arila i são fornecidos compostos inibidores sglt2 tendo a fórmula (i) onde r1, r2 e r2a são independentemente hidrogênio, oh, or5 , alquila inferior, cf3, ochf2, ocf3, sr5i ou halogênio, ou dois dentre r1, r2 e r2a juntamente com os carbonos os quais são ligados, podem formar um carbociclo ou heterociclo com cinco, seis ou sete membros anelados; r3 e r4 são independentemente hidrogênio, oh, or5a, oarila, och2arila, alquila inferior, cicloalquila, cf3, -ochf2, - ocf3, halogênio, -cn, -co2r5b, -co2h, -cor6b, -ch (oh) r6c, - ch (or5h) r6d, -conr6r6a, -nhcor5c, -nhso2r5d, -nhso2arila, arila, -sr5e -sor5f, -so2r5g, -so2arila, ou um heterociclo com cinco, seis ou sete membros, ou r3 e r4 juntamente com os carbonos aos quais são ligados formam um heterociclo ou carbociclo com cinco, seis ou sete membros anelados; r5, r5a, r5b, r5c, r5d, r5e, r5f, r5g, r5h e r5i são independentemente alquila inferior; r6, r6a, r6b, r6c e r6d são independentemente hidrogênio, alquila, arila, alquilarila ou cicloalquila, ou r6 e r6a juntamente com o nitrogênio ao qual são ligados formam um heterociclo com cinco, seis ou sete membros anelados; a é o, s, nh ou (ch2)n onde n é 0 - 3. também é fornecido um método para tratar diabetes e doenças relacionadas empregando uma quantidade de inibição de sglt2 do composto acima individualmente ou em combinação com outro agente antidiabético ou outro agente terapêutico.

First Claim
Family

- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Country Designations

Patent Owner(s)
- Owner owned or assignment not recorded
International Classification(s)
Inventor(s)
- No Inventor to display
Cited Art Landscape
- No Cited Art to Display

Legal Events

Matter Detail

Renewals Detail

Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:

Add to additional portfolios:

Note
The template below is formatted to ensure compatibility with our system.
Provide tags with | separated like (tags1|tags2).
Maximum length is 128 characters for Customer Application No
Mandatory Fields * - 'MatterType','AppType','Country','Title','SerialNo'.
Acceptable Date Format - 'MM/DD/YYYY'.
Acceptable Filing/App Types -
- Continuation/Divisional
- Original
- Paris Convention
- PCT National
- With Priority
- EP Validation
- Provisional Conversion
- Reissue
- Provisional
- Foreign Extension
Acceptable Status -
- Pending
- Abandoned
- Unfiled
- Expired
- Granted
Acceptable Matter Types -
- Patent
- Utility Model
- Supplemental Protection Certificate
- Design
- Inventor Certificate
- Plant
- Statutory Invention Reg
Advertisement
Advertisement
Advertisement

Recipient Email Address

Recipient Email Address

Comment
Recipient Email Address

Success
E-mail has been sent successfully.
Failure
Some error occured while sending email. Please check e-mail and try again!
Important Notes on Latency of Status data
This Status indicator is an estimation based on the relevant document kind code. As such, it status will only indicate "Published" or "Granted". Expired, lapsed or abandoned statuses are not available in this release. Please refer to the legal status information for more information.
This status should not be taken as legal conclusion. No representations are made as to the accuracy of the status provided. Please consult a legal professional before relying on this status information.
Important Note on Priority Date data
This priority date is an estimated earliest priority date and is purely an estimation. This date should not be taken as legal conclusion. No representations are made as to the accuracy of the date listed. Please consult a legal professional before relying on this date.
Only for Granted EP cases
EP validations represent the countries in which the EP patent may be in force. Data is based on reporting from the various EP contracting states. The reporting consistency can vary across the countries.